New Testing Proves Virox™ AHP® Wipe Formulations Effective against SARS-CoV-2
Virox™ is pleased to announce that several of our Accelerated Hydrogen Peroxide® (AHP®) wipe formulations have been validated by independent testing and proven efficacious against SARS-CoV-2, the virus that causes COVID-19 disease. As industry leaders in infection prevention, our mission is to ensure our customers are protected against the threat of emerging disease outbreaks in all of the markets we serve.
As COVID-19 began to spread worldwide, public health officials issued recommendations to practice physical distancing, regular hand hygiene and cleaning and disinfection to prevent the spread of the SARS-CoV-2 virus. In the event of outbreaks caused by emerging viral pathogens, both the EPA and Health Canada rely on their Emerging Viral Pathogen policies to determine the expected effectiveness of disinfectants against a newly identified virus. All Virox AHP-based formulations meet the criteria for emerging viral pathogens, and can be found on the list of approved disinfectants for both Canada and the United States for use against SARS-CoV-2. The recent testing provides an added layer of confidence that AHP-based formulations have directly demonstrated the ability to kill SARS-CoV-2 and will be submitted to both the EPA and Health Canada for review and approval at which time product labels and marketing materials will be updated.
Since the SARS outbreak hit North America in 2003, Virox has been at the forefront in the fight against infectious disease outbreaks. With an initial focus in human healthcare, Virox has brought safer, more environmentally-responsible disinfectants into a wide range of other industries, including animal health, dental, professional beauty, life sciences, mold remediation and beyond. In addition to developing innovative disinfectant technologies, we are equally committed to providing education and technical support to help facilities optimize their infection prevention protocols.